Trevi Therapeutics, Inc. (TRVI) Stock Analysis & Investment Frameworks
Trevi Therapeutics, Inc. (TRVI) stock analysis on Invetso. Review Trevi Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Trevi Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Trevi Therapeutics, Inc. Key Financial Metrics
- Market Cap: $1.86B
- Revenue: $N/A
- ROE: -23.59%
- ROIC: -18.46%
- Dividend Yield: N/A
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Trevi Therapeutics, Inc. Investment Frameworks
Invetso analyzes Trevi Therapeutics, Inc. (TRVI) across the following frameworks:
- Trevi Therapeutics, Inc. 10Y Growth Potential
- Trevi Therapeutics, Inc. Scenario Analysis
- Trevi Therapeutics, Inc. Risks & Opportunities
- Trevi Therapeutics, Inc. Economic Moat
- Trevi Therapeutics, Inc. Business Model
- Trevi Therapeutics, Inc. Management
- Trevi Therapeutics, Inc. SWOT Analysis
- Trevi Therapeutics, Inc. Porter's 5 Forces
- Trevi Therapeutics, Inc. PESTLE Analysis
- Trevi Therapeutics, Inc. ESG Analysis